
Opinion|Videos|November 18, 2024
Exploring Emerging Therapies in Vitiligo
Author(s)Seemal Desai, MD, FAAD
The panelist discusses how emerging targeted therapies like Janus kinase inhibitors and combination treatment approaches are transforming vitiligo management, with treatment selection guided by disease patterns, progression rates and individual patient response, while acknowledging the need for systematic assessment and alternative strategies for treatment-resistant cases.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the most promising new vitiligo treatments?
- How has this knowledge shaped current treatment approaches and new therapies?
- How do vitiligo progression patterns affect treatment decisions and long-term management?
- Describe your process to assess and manage treatment-resistant disease.
- What is the role of newer targeted therapies in such cases?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
4
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
5























